Dear Editor,
The SARS-CoV-2 Omicron variant has rapidly displaced the Delta variant and spread across the world. The Omicron variant harbors over 60 mutations, and 15 of the mutations are located in the receptor-binding domain (RBD).1 Compared with parental virus and previous variants, the Omicron variant is characterized by decreased hospitalization rates and less severe disease in patients.2 However, how the Omicron variant reduces pathogenicity remains unclear. The Omicron variant has diminished fusogenicity, although the underlying mechanism is unknown. Fusogenicity was shown to be associated with pathogenicity in SARS-CoV-2 patients.3 The L452R mutation, one of the most frequent mutations (Fig. 1a, b), is the only RBD domain mutation that emerges in the Delta variant but is absent in the Omicron variant (Fig. 1c). It has been reported that L452R mutation increases SARS-CoV-2 fusogenicity and infectivity.4 Here, we developed an L452R mutated Omicron variant (Omicron-L452R) and found that the Omicron-L452R variant rescued fusogenicity and strengthened the high infectivity by enhancing the cleavage of the spike protein. Notably, Omicron-L452R greatly enhanced the ability of Omicron to infect lung tissues of humanized ACE2 mice. Furthermore, the Omicron-L452R variant dramatically enhanced glycolysis in host cells. Our data suggest that the decreased fusogenicity of the Omicron variant is due to a lack of the L452R mutation present in the Delta variant.
SARS-CoV-2-infected cells fuse with neighboring cells to form multinucleated cells named syncytia. Syncytia may contribute to virus transmission, immune evasion, and pathogenicity. It has been reported that infected syncytial pneumocytes are present in 87% of deceased SARS-CoV-2 patients, and syncytia formation correlates with disease severity. The Omicron variant has exhibited diminished fusogenicity and pathogenicity compared with the Delta variant and parental virus. Because of the essential role of the L452R mutation in SARS-CoV-2 fusogenicity and infectivity, we investigated the effect of L452R on the fusogenicity of the Omicron variant. Consistent with a previous report, compared to the parental virus (B.1), the Omicron variant almost lost fusogenicity, and the Delta variant demonstrated greatly enhanced fusogenicity. Importantly, the Omicron-L452R variant exerted markedly enhanced fusogenicity (Fig. 1d). Efficient syncytia formation depends on the cleavage of the spike (S) protein at the S1/S2 site.5 Next, we investigated the effect of variants and parental virus on spike protein cleavage. In agreement with the syncytia formation assay, the Omicron variant reduced the cleavage of the SARS-CoV-2 S protein compared with the Delta variant and parental virus, whereas the Omicron-L452R variant greatly enhanced the cleavage of the S protein (Fig. 1e). It has been reported that mutations in the Omicron spike protein introduce electrostatic contacts and enhance the interaction between the S1 and S2 subunits, which results in reduced S protein cleavage. Whether the L452R-Omicron variant promotes cleavage of the S protein by decreasing the interaction of the S1 and S2 subunits remains to be investigated.
The Omicron variant spike protein binds human ACE2 and facilitates its entrance and confers Omicron increased infectivity in human primary nasal epithelial cultures and other ACE2-positive cells. Consistent with previous data, the pseudovirus infection assay indicated that the Omicron variant demonstrated enhanced entry into Huh-7, 293T-ACE2, and H1299-ACE2 cells compared to the Delta variant and parental virus, and the Omicron-L452R variant further increased viral entry into these cells (Fig. 1f). In summary, the Omicron-L452R variant not only rescued fusogenicity but also strengthened infectivity, suggesting that the Omicron-L452R variant is a very risky variant.
To obtain available energy and nucleotides for viral replication, SARS-CoV-2 induces metabolic reprogramming in host cells in a manner similar to the Warburg effect in cancer cells. However, the effect of the Delta and Omicron variants on glycolysis has not been investigated. We found that the Delta and Omicron-L452R variants increased lactate production more than the Omicron variant in Huh-7, 293T-ACE2, and H1299-ACE2 cells, although the Omicron variant enhanced lactate production in H1299-ACE2 cells (Fig. 1g). In agreement with lactate production, the extracellular acidification rate (ECAR) assay indicated that the Delta and Omicron-L452R variants highly stimulated glycolysis in Huh7, H1299-ACE2, and 293T-ACE2 cells, while the Omicron and parental viruses slightly increased glycolysis flux (Fig. 1h). Therefore, the Delta and Omicron-L452R variants may use enhanced glycolysis to support their high fusogenicity and high infectivity. It has been shown that SARS-CoV-2 infection increases the expression of hexokinase (HK2) and pyruvate kinase isozyme (PKM), key rate-limiting enzymes in glycolysis, and promotes lactate production, resulting in enhanced host glycolysis. Whether the Omicron-L452R variant stimulates host glycolysis by regulating glycolysis-related enzymes remains to be elucidated.
Next, the infectivity of the Omicron-L452R variant was investigated in K18-hACE2 transgenic mice in vivo. The bioluminescence of infected mice was measured to indicate the pseudovirus infection severity. Consistent with live SARS-CoV-2 virus, the Delta variant has the highest infectivity. The Omicron variant modestly inhibited infectivity, whereas Omicron-L452R significantly enhanced infectivity (Fig. 1i). qRT-PCR was performed to detect the infected pseudovirus copies. Compared to mice infected with the parental virus, the virus copies in the Omicron-infected mouse lung tissues were reduced, while the virus copies in the Omicron-L452R variant-infected mouse lung tissues were markedly enhanced (Fig. 1j). Therefore, the Omicron-L452R variant enhanced the ability of Omicron to infect lung tissues in vivo.
The Omicron variant is characterized as less pathogenic and more transmissible than the parental and previous variants, which may be due to crystal structure changes caused by over 30 mutations in the Spike protein. In this investigation, we found that the further mutation of L452R in the Omicron variant not only rescued fusogenicity but also strengthened the high infectivity. Importantly, the Omicron-L452R variant enhanced the ability of Omicron to infect lung tissues of humanized mice. By dramatically enhancing the anaerobic glycolysis of host cells, the Omicron-L452R variant obtains enough energy and nucleotide material to replicate in human cells. Taken together, the L452R mutation dramatically increases the risk of the Omicron variant. Our data explain why the Omicron variant has decreased fusogenicity and suggest that whether the L452R mutation is present in the Omicron variant should be closely monitored, and specific therapeutic antibodies and vaccines that target the L452R mutation should be developed.
Data availability
The data used to support the findings of this study are available from the corresponding author upon reasonable request.
References
Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 1–12 (2022).
Maslo, C. et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA 327, 583–584 (2021).
Rajah, M. M., Bernier, A., Buchrieser, J. & Schwartz, O. The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. J. Mol. Biol. 1, 167280 (2021).
Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29, 1–13 (2021).
Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293–299 (2021).
Acknowledgements
This work was supported by the National Key Research and Development Program of China (2017YFA0505602), the National Natural Science Foundation (81930078, 81872246, 81802756, 31470773 and 81773135) and Military Medical Innovation Project (18CXZ047).
Author information
Authors and Affiliations
Contributions
L.D. and Q.Y. conceived the project, designed the experiments, and analyzed the data. Y.Z., T.Z., and Y.F. performed the experiments and analyzed the data, aided by J.L. L.D., Y.Z., and Q.Y. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics declarations
Animal studies followed an animal use protocol approved by the Institutional Animal Care and Use Committee of Beijing Institute of Biotechnology (IACUC-DWZX-2021-577).
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhang, Y., Zhang, T., Fang, Y. et al. SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and infectivity as well as host glycolysis. Sig Transduct Target Ther 7, 76 (2022). https://doi.org/10.1038/s41392-022-00941-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-022-00941-z
This article is cited by
-
Analysis of SARS-CoV-2 omicron mutations that emerged during long-term replication in a lung cancer xenograft mouse model
Virus Genes (2024)
-
Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host
Signal Transduction and Targeted Therapy (2023)
-
Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective
Molecular Biology Reports (2023)
-
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants
Journal of Clinical Immunology (2023)
-
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Genome Medicine (2022)